NCT00565981 - A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Response | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

February 13, 2008

Study Completion Date

February 13, 2008

Conditions

B-cell Chronic Lymphocytic Leukemia

Interventions

DRUG

Fludarabine phosphate

orally, 40 mg/m2 d1-3 q4w, x4 cycles

DRUG

Alemtuzumab

subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose

Trial Locations (8)

Landeskrankenhaus Feldkirch, Feldkirch

A.ö. Landeskrankenhaus Fürstenfeld, Fürstenfeld

Universitätsklinik Innsbruck/ Klinik für Innere Medizin, Innsbruck

A.ö. Landeskrankenhaus Leoben, Leoben

Krankenhaus der Stadt Linz, Linz

St. Johanns LK, Salzburg

A.ö. Krankenhaus der Landeshauptstadt St. Pölten, Sankt Pölten

Klinikum Kreuzschwestern Wels GmbH, Wels